---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018791"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:57:56.926500+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Imunon Q1 net loss $4.9M ($0.52/shr), appoints Stacy Lindborg as CEO; OVATION 2 data expected mid-2024

## Summary
- Net loss of $4.9M ($0.52/shr) vs $5.6M ($0.68/shr) in Q1 2023; operating expenses down 12% to $5.0M.
- Cash and investments $9.8M; believes funding sufficient through end of 2024.
- Stacy Lindborg appointed President and CEO effective May 13, 2024; previously a director and Co-CEO of BrainStorm.
- OVATION 2 Study of IMNN-001 in advanced ovarian cancer: interim PFS delay ~3 months, OS improvement ~9 months; final readout mid-2024.
- FDA cleared IND for IMNN-101 seasonal COVID booster; Phase 1 starting Q2 2024. Received $1.3M non-dilutive from NJ NOL sale.

## SEC filing metadata
- accession: 0001493152-24-018791
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/0001493152-24-018791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018791
- JSON: https://secwatch.observer/filing/0001493152-24-018791.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018791.txt

## Key facts
- Earnings Releases
  Imunon, Inc. reported financial results for quarter ended March 31, 2024.
  - Period: quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/0001493152-24-018791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.